Novartis AG is a global healthcare company that specializes in developing and manufacturing innovative pharmaceuticals and medical products. The company focuses on research-driven solutions in various therapeutic areas, including oncology, cardiology, immunology, and neuroscience, among others. Novartis is committed to improving patient health by providing high-quality medications and treatments, and it invests significantly in research and development to discover and deliver new therapies. In addition to its pharmaceutical division, Novartis also offers generics and biosimilars through its Sandoz division, making healthcare more accessible to patients worldwide. Read More
The London International Invention & Trade Expo, recognised globally as a benchmark for scientific and technological innovation and previously awarded to leading companies including Novartis and Bayer, has honoured Bionique with a Gold Medal for its breakthrough women’s health product — Bionique FEMBIOTIC Women ’ s Probiotics Complex . The product has also been distinguished with a Gold Medal at the Prix Eiffel International Invention and Innovation Contest , further underscoring its innovative leadership in women’s microbime science.
European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have effectively soothed widespread concerns about an "AI bubble." This upturn signals renewed investor confidence in the region's economic stability and the tangible value being
BioMedWire Editorial Coverage : As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (“GAAP”) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( profile ) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (“JV”) entity GMP Bio, driven by a new independent valuation indicating a potential step-up in asset value. This key shift strengthens Oncotelic Therapeutics position in the oncology space as the company works to make a difference, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and…
AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (JV) entity GMP Bio, driven by a new independent valuation https://nnw.fm/5K7hg indicating a potential step-up in asset value. This key shift strengthens Oncotelic Therapeutics position in the oncology space as the company works to make a difference, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE)
Novartis (NVS) offers a strong 3.31% dividend yield with a history of reliable payouts and growth, backed by excellent profitability and financial health.
Suzhou, China, November 15, 2025 -- March 12–14, 2026, The global biopharmaceutical industry will gather in Suzhou as BIOCHINA2026 returns for its 11th edition under the theme “Fusion Forward.” Recognized as one of Asia’s most influential platforms, BIOCHINA provides a premier venue for scientific discussion, industry insights, and strategic collaboration.
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in mergers and acquisitions (M&A), the transformative power of artificial intelligence (AI), and an evolving investor landscape. With the global biotechnology
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This burgeoning field is set to dramatically enhance the shelf-life and effectiveness of medications, addressing long-standing inefficiencies in traditional drug development. By moving beyond time-consuming, empirical trial-and-error methods, [...]
Suzhou, China - The global biopharmaceutical industry will gather in Suzhou as BIOCHINA2026 returns for its 11th edition under the theme “Fusion Forward.” Recognized as one of Asia’s most influential platforms, BIOCHINA provides a premier venue for scientific discussion, industry insights, and strategic collaboration.
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This development marks a significant step forward in streamlining the notoriously complex and expensive process of bringing new therapies to patients, promising substantial reductions in costs and a [...]
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the heels of the company's announcement regarding the pricing of a $50 million underwritten public offering, a move that is
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable tension between investor optimism and concerns over valuation. As of November 2025, the AI market stands at a pivotal juncture, with a concentrated surge in mega-cap AI players driving overall market [...]
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design (IPD) has successfully leveraged AI to design antibodies from scratch, achieving unprecedented atomic precision. This groundbreaking development, primarily driven by a sophisticated generative AI model [...]
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
